Sanofi is jet­ti­son­ing its in­fec­tious dis­ease unit to Evotec — hand­ing over cash, staff and a pipeline

Sanofi is spin­ning out its in­fec­tious dis­ease re­search unit to Evotec, the Ger­man con­tract de­vel­op­ment or­ga­ni­za­tion known for its deal savvi­ness. And the Paris-based phar­ma gi­ant $SNY — suf­fer­ing from a long drought that has blight­ed its in­ter­nal R&D ops — is hand­ing over €60 mil­lion (around $74 mil­lion) up­front for the op­er­a­tion along with con­tin­ued fi­nanc­ing, 10 ex­per­i­men­tal in­fec­tious dis­ease projects and 100 of its staffers to get it all go­ing.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.